Bio Medica Laboratories Ltd is launching a book-built IPO worth ₹52.43 crore, comprising a fresh issue of 0.34 crore shares (₹47.19 crore) and an offer for sale of 0.04 crore shares (₹5.24 crore).
The IPO will open for subscription from May 21 to May 25, 2026. The allotment is likely on May 26, 2026, and the shares are expected to list on the SME platform of the National Stock Exchange of India on May 29, 2026.
The price band has been fixed at ₹132–₹139 per share with a lot size of 1,000 shares. Retail investors must apply for a minimum of 2,000 shares (₹2,78,000), while HNI investors need at least 3 lots (3,000 shares) worth ₹4,17,000.
The issue is managed by Narnolia Financial Services Ltd as the book-running lead manager, Skyline Financial Services Pvt Ltd as the registrar, and Prabhat Financial Services Ltd as the market maker.
Bio Medica Laboratories IPO Objectives
Bio Medica Laboratories Ltd plans to use the IPO funds for the following purposes:
- Loan repayment: ₹6.50 crore will be used to reduce existing debt.
- New manufacturing facility: ₹28.50 crore will be spent to expand production capacity at the current premises.
- General corporate purposes: Remaining funds will be used for day-to-day business and other company needs.
About Bio Medica Laboratories Limited
Bio Medica Laboratories Ltd, incorporated in August 2015, is engaged in the manufacturing of pharmaceutical parenteral formulations. The company produces a wide range of ethical, generic, and over-the-counter medicines in both liquid and dry-powder injectable forms, available in single-dose and multi-dose formats for human as well as veterinary healthcare. Its portfolio includes 58 liquid injectable products and 15 dry-powder injectables, along with various branded and generic medicines.
The company follows a B2B contract manufacturing model, where it develops formulations for other pharmaceutical companies based on their specific requirements. It holds GMP and GLP certifications issued by the Food & Drugs Administration, Madhya Pradesh, and operates two manufacturing facilities in Indore. Its key strengths include a diversified product portfolio, experienced management and workforce, strong quality standards, and long-standing relationships with clients.
How To Apply for the Bio Medica Laboratories IPO Online?
- Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
- Locate the IPO Section: Navigate to the 'IPO' section on the platform.
- Select IPO: Find and select the Bio Medica Laboratories IPO from the list of open IPOs.
- Enter the Lot Size: Specify the number of lots you want to bid for.
- Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
- Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.
How To Check the Allotment Status of Bio Medica Laboratories IPO?
Steps to check IPO allotment status on Angel One’s app:
- Log in to the Angel One app.
- Go to the IPO Section and then to IPO Orders.
- Select the individual IPO that you had applied for and check the allotment status.
- Angel One will notify you of your IPO allotment status via push notification and email.
Contact Details of Bio Medica Laboratories Limited
Registered office: Bio Medica Laboratories Ltd. Address: Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate (Indore), Indore, Madhya Pradesh, 452015
Phone: +91 7314102751
E-mail: companysecretary@biomedica.co.in
Bio Medica Laboratories IPO Reservation
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
| QIB Shares Offered | 36,000 | 1.00% | 0.95% |
| NII (HNI) Shares Offered | 17,55,000 | 48.98% | 46.53% |
| └ bNII (> ₹10L) | 11,70,000 | — | 31.02% |
| └ sNII (< ₹10L) | 5,85,000 | — | 15.51% |
| Retail Shares Offered | 17,92,000 | 50.01% | 47.51% |
| Market Maker (Firm Reservation) | 1,89,000 | — | 5.01% |
| Total Shares Offered | 37,72,000 | 100% | 100% |
Bio Medica Laboratories IPO Lot Size Details
| Application Category | Lots | Shares | Amount |
| Individual Investors (Retail) – Min | 2 | 2,000 | ₹2,78,000 |
| Individual Investors (Retail) – Max | 2 | 2,000 | ₹2,78,000 |
| S-HNI – Min | 3 | 3,000 | ₹4,17,000 |
| S-HNI – Max | 7 | 7,000 | ₹9,73,000 |
| B-HNI – Min | 8 | 8,000 | ₹11,12,000 |
Bio Medica Laboratories IPO Promoter Holding
The promoters of the company include Mr. Mukesh Mehta and Mr. Pradeep Mehta.
| Share Holding Pre-Issue | 99.99% |
| Share Holding Post Issue |
Note: Equity dilution will be determined by subtracting the Shareholding Post Issue from the Shareholding Pre Issue.
Key Performance Indicators for Bio Medica Laboratories IPO
| KPI | Nov 30, 2025 | Mar 31, 2025 |
| ROE | 54.41% | 99.59% |
| ROCE | 23.22% | 48.20% |
| Debt/Equity | 2.23 | 1.02 |
| RoNW | 54.41% | 99.59% |
| PAT Margin | 30.35% | 25.64% |
| EBITDA Margin | 47.11% | 39.83% |
| Price to Book Value | 8.66 | — |
Bio Medica Laboratories IPO Registrar and Lead Managers
Bio Medica Laboratories IPO Lead Managers
- Narnolia Financial Services Ltd
Registrar for Bio Medica Laboratories IPO
Skyline Financial Services Pvt.Ltd.
- Contact Number: 02228511022
- Email Address: ipo@skylinerta.com
Financial Performance of Bio Medica Laboratories Limited
| Particulars | Nov 30 2025 | Mar 31 2025 | Mar 31 2024 | Mar 31 2023 |
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 8.66 | 9.79 | 2.50 | 0.33 |
| EBITDA | 13.45 | 15.21 | 5.63 | 1.70 |
| Net Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Reserves & Surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total Borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
Bio Medica Laboratories Limited Peer Comparison
| Company Name | EPS (Basic) | NAV (₹/Share) | P/E (x) | RoNW (%) | P/BV Ratio |
| Bio Medica Laboratories Ltd. | 10.67 | 16.05 | — | 99.59 | — |
| Zenotech Laboratories Limited | 0.92 | 15.76 | — | 6.01 | 4.13 |
| Shukra Pharmaceuticals Limited | 0.22 | 1.43 | 47.57 | 15.90 | 20.00 |
Strengths and Opportunities of Bio Medica Laboratories Limited
- The company focuses on B2B contract manufacturing, producing liquid and dry powder injectable medicines for major pharmaceutical brands.
- It follows strict quality and regulatory standards, with GMP and GLP certifications ensuring reliable manufacturing and compliance.
- It has a diverse product range of injectables for both human and veterinary healthcare in single-dose and multi-dose formats.
- The business has shown strong financial growth, with consistent improvement in profits over recent years.
- The promoters bring over 18 years of experience in the pharmaceutical industry.
- Funds from the IPO will help set up a new manufacturing facility, which can increase production capacity and efficiency.
Risks and Threats of Bio Medica Laboratories Limited
- The company depends heavily on a few large clients, with the top 5 customers contributing over 60% of revenue. Losing any major client could affect sales significantly.
- The injectable pharma business requires strict regulatory approvals and inspections. Any failure to meet cGMP norms could lead to production stoppages or warning notices.
- Product quality issues could result in legal claims, contract loss, and reputational damage.
- The company has high debt and unsecured loans, creating pressure on cash flow and liquidity.
- Part of the IPO proceeds will be used to repay loans. If funds are not raised or used effectively, debt and interest costs may remain high.
- Like any equity investment, there is capital risk, especially if post-listing demand is weak or trading activity remains low.
